MI Dendream, Charles River Laboratories (CRL) is a CDMO, not a biotech. CRL would hurt its primary target customer base if it acquired a cell therapy company. CRL acquired Cognate so that CRL could market its CDMO services to cell and gene therapy companies worldwide. If CRL tried to acquire NWBio, that would harm CRL’s core business, and alienate current and prospective cell and gene therapy customers, who may have drugs or biologics that compete, or will compete with the DCVax vaccine platform.
Also, CRL’s current market cap is less than $24 billion. They would not have enough capital to acquire NWBio, but they could acquire Advent.
Market Data 
Markets 
AI
